Endpoints News 生物医药· Reynald Castaneda·· 23 天前AI 评分33
Astellas 从 Audax Biosciences 获得临床前 IL-12 肿瘤药物独家许可选择权
Astellas buys option on preclinical IL-12 cancer drug from Audax Biosciences
AI 导读
Astellas 已从澳大利亚生物技术公司 Audax Biosciences 获得一款临床前 IL-12 肿瘤药物的独家许可选择权。这项免疫肿瘤资产交易涉及 2.85 亿美元。
正文
Astellas has taken an exclusive option to license a preclinical immuno-oncology asset from Australian biotech Audax Biosciences.
The deal features $285 million that covers the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news